Coupling of Heterotrimeric Gi Proteins to the Erythropoietin Receptor*

Christine GuillardDagger , Stany ChrétienDagger , Ralf Jockers§, Serge FichelsonDagger , Patrick MayeuxDagger , and Véronique DuprezDagger

From the Dagger  INSERM, U 363 and § CNRS-UPR 0415, Institut Cochin de Génétique Moléculaire, 75014 Paris, France

Received for publication, April 26, 2000, and in revised form, October 20, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To identify new proteins involved in erythropoietin (Epo) signal transduction, we purified the entire set of proteins reactive with anti-phosphotyrosine antibodies from Epo-stimulated UT7 cells. Antisera generated against these proteins were used to screen a lambda EXlox expression library. One of the isolated cDNAs encodes Gbeta 2, the beta 2 subunit of heterotrimeric GTP-binding proteins. Gbeta and Galpha i coprecipitated with the Epo receptor (EpoR) in extracts from human and murine cell lines and from normal human erythroid progenitor cells. In addition, in vitro Gbeta associated with a fusion protein containing the intracellular domain of the EpoR. Using EpoR mutants, we found that the distal part of the EpoR (between amino acids 459-479) was required for Gi binding. Epo activation of these cells induced the release of the Gi protein from the EpoR. Moreover in isolated cell membranes, Epo treatment inhibited ADP-ribosylation of Gi and increased the binding of GTP. Our results show that heterotrimeric Gi proteins associate with the C-terminal end of the EpoR. Receptor activation leads to the activation and dissociation of Gi from the receptor, suggesting a functional role of Gi protein in Epo signal transduction.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activation of the EpoR1 elicits multiple intracellular signals that ultimately lead to cell division and differentiation of erythroid progenitor and precursor cells. One primary signaling event following receptor activation is the phosphorylation of certain cellular proteins on tyrosine residues (1, 2). Interaction of Epo with its receptor results in the activation of the cytoplasmic tyrosine kinase JAK2 and in the phosphorylation of the intracellular domain of EpoR (3-5). Tyrosine phosphorylated residues on EpoR then constitute binding sites for other intracellular proteins that become eventually tyrosine phosphorylated. Other tyrosine kinases are also activated in response to Epo such as c-Fes (6), Lyn (7), and Syk (8). Tyrosine phosphorylated proteins may be recruited directly to the EpoR via their Src homology domains or indirectly through adaptor or scaffold proteins. Several tyrosine kinase substrates phosphorylated upon Epo activation have been identified including STAT5 transcription factor (9), SHP-2 tyrosine phosphatase (10), Shc (11), phospholipase C-gamma 1 (12), Vav (13), c-Cbl (14), IRS-2 (15), GAB-1 (16), and CrkL (17). Yet the relations between all the components involved in Epo signaling as well as the identification of their respective targets are only partially elucidated, and EpoR may activate other additional signal transduction pathways.

In an attempt to characterize substrates for epidermal growth factor (EGF) receptor, Fazioli et al. (18) developed an expression cloning strategy for cDNAs encoding EGF receptor substrates. The approach relied on batch purification of an entire set of putative substrates, achieved by immunoaffinity chromatography using anti-phosphotyrosine antibodies (19, 20). Antisera generated against the entire pool of purified proteins were subsequently used for the screening of cDNAs expression libraries. We applied this methodology to identify new cDNAs encoding signaling proteins involved in Epo activation, either tyrosine phosphorylated proteins or proteins bound to these proteins. In the present work we report that one of these cDNAs encodes Gbeta 2, the beta 2 subunit of heterotrimeric GTP-binding proteins, or G proteins.

G proteins traditionally associate with G protein-coupled receptors (GPCRs) that contain seven membrane-spanning domains. G proteins function as intermediates that couple cell surface receptors to intracellular effectors. Heterotrimeric G proteins are made of three polypeptides: an alpha  subunit that binds and hydrolyzes GTP, and beta gamma subunits that form a functional monomer. Receptor activation induces the exchange of GDP for GTP on the Galpha subunit. Once GTP is bound, the alpha  subunit dissociates both from the receptor and from beta gamma . The free alpha  and beta gamma subunits each activate target effectors. However, a number of single-spanning transmembrane receptors such as receptors for EGF (21), insulin and insulin-like growth factor (IGF)-I and IGF-II (22-25), fibroblast growth factor (26), and T lymphocyte receptors (27, 28) have been reported to activate G proteins. In some cases a physical association, in addition to a functional coupling, has also been demonstrated between a single-spanning membrane receptor and G proteins (29-32).

Heterotrimeric G proteins could be important intermediates in the signal transduction of hematopoietic cytokines. Changes in the expression level and GTPase activity of Galpha 16, a member of the Gq family of G proteins uniquely expressed in hematopoietic cells, may modulate cellular proliferation or differentiation in T lymphocytes and in MB-02 erythroleukemia cells (33, 34). Pertussis toxin (PT) modifies the response to several hematopoietic growth factors. PT catalyzes the ADP-ribosylation of the Gi family of G proteins and uncouples G proteins from surface receptors. PT inhibits the signal transduction and/or proliferation induced by interleukin (IL)-1, IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF) and colony-stimulating factor-1 (CSF-1) (35-38) in hematopoietic cells. Expression of a dominant negative mutant of Galpha i2 also inhibits cell proliferation in response to CSF-1 in BAC 1.2F5 macrophage cell line (39). In erythroid precursor cells a pertussis toxin-sensitive G protein identified as Galpha i2 is required for the regulation of voltage-independent calcium channels by Epo (40, 41). The increase in [Ca2+]i appears to be a stage of differentiation specific and restricted to differentiating erythroblasts (42).

In the present study we demonstrate the constitutive association of Gi with the EpoR in hematopoietic cell lines as well as in erythroid progenitors. We show that the C-terminal region of EpoR is required for Gi protein binding. In addition, Epo activates G protein in cell membranes and induces the release of Gi bound to the EpoR in hematopoietic cells. Thus, EpoR appears to be physically and functionally coupled to G proteins.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies and Reagents-- Anti-phosphotyrosine (anti-Tyr(P)) monoclonal antibodies 4G10 and PY72 were produced from hybridoma cell lines kindly provided by B. Drucker (Portland, OR) and B. Sefton (La Jolla, CA), and were affinity purified by chromatography on phosphotyramine. Anti-EpoR antiserum used for immunoprecipitation was produced against a fusion protein between glutathione S-transferase and the cytoplasmic portion of human EpoR. Peroxydase-conjugated anti-rabbit antibodies were purchased from Amersham Pharmacia Biotech. Antibodies specific for human EpoR used for immunoblotting were purchased from Santa Cruz (sc-695) and anti-JAK2 antiserum from Upstate Biotechnology Inc. (catalog number 06-255). The fusion protein between the maltose-binding protein (MalE) and the cytoplasmic region of EpoR was described previously (43). Purified recombinant human Epo (specific activity, 120,000 units/mg) was a gift of Dr. M. Brandt (Roche Molecular Biochemicals). Pertussis toxin was purchased from Alexis, ATP was from Amersham Pharmacia Biotech, and GTP and GTPgamma S were from Sigma.

DNA Constructs and Expression Vectors-- The murine EpoR mutant F1-Y58 that contains a deletion between Glu377 and Tyr431 was described previously (9). A panel of EpoR deletion mutants was produced from polymerase chain reaction-amplified fragments. In mutants -41, -24, -20, and -5, stop codons were inserted just after codons 442, 459, 463, and 478, respectively (see Fig. 6). All receptor constructs were subcloned into a modified pCDNA3 expression vector where the cytomegalovirus promotor was changed to Rous sarcoma virus and the neomycin resistance gene was replaced by puromycin. The fidelity of all constructs was confirmed by sequencing.

Cell Lines and Stimulation-- The human leukemic cell line UT7 (44) was maintained in alpha -minimum essential medium supplemented with 5% fetal calf serum, penicillin, streptomycin, 2 mM L-glutamine, and 2 units/ml Epo. TF-1 (45) and MO7E cell lines (46) were cultured in alpha -minimum essential medium supplemented with 10% fetal calf serum and 2.5 ng/ml GM-CSF. TF-1-ER (47) and MO7E-ER (8) cell lines were obtained after infection of TF-1 and MO7E with an amphotropic virus encoding a murine EpoR and were cultured with Epo. FDCP-1 myeloid cells were grown in alpha -minimum essential medium supplemented with 5% fetal calf serum and 3% WEHI conditioned medium as a source of IL-3. After transfection with EpoR expression vectors and selection in Epo, cells were grown in the presence of Epo. 32D myeloid cells expressing wild-type EpoR and W282R mutant (48) were generously provided by G. D. Longmore (St. Louis, MO). Erythroid progenitors were purified from human umbilical cord blood cells as described previously (49). Briefly CD34+ cells were cultured for 7 days in serum-free conditions in the presence of interleukin-3, interleukin-6, and stem cell factor. CD36+ cells were then purified and expanded for 2 additional days in the presence of the same cytokines plus 2 units/ml Epo. CHO-ER cell line, a kind gift of E. Goldwasseur (Chicago, IL), was cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.

For Epo triggering experiments, exponentially growing UT7 or TF-1 cells were washed and incubated for 16-18 h in Iscove's modified Dulbecco's medium supplemented with 0.4% bovine serum albumin and 20 µg/ml iron saturated transferrin, in serum-free conditions. Normal erythroid progenitors were washed and incubated for 4 h in serum-free Iscove's modified Dulbecco's medium in the presence of 5% bovine serum albumin, 50 µg/ml insulin, and 1 mg/ml transferrin. FDCP-1 cells expressing EpoR and MO7E-ER cells were Epo starved by replacing Epo, respectively, with WEHI conditioned medium and GM-CSF one to 2 days prior to stimulation. The cells (1 × 107/ml) were stimulated with 10 units/ml Epo at 37 °C as described in the text.

Immunoaffinity Chromatography-- Cells (1 × 109) were lysed on ice with buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM orthovanadate, 2 mM EGTA, 30 mM disodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptine, 10 µg/ml aprotinine, 10 µg/ml EG4, and 1 µg/ml pepstatine. Anti-Tyr(P) columns were prepared by covalently cross-linking affinity purified PY72 monoclonal antibody to Sepharose beads (Hi TrapTM NHS-activated Sepharose from Amersham Pharmacia Biotech). Solubilized proteins were applied to the anti-Tyr(P) column (1 ml) using a fast protein liquid chromatography system. The column was washed successively with 10 column volumes of lysis buffer and 30 volumes of washing buffer (same as lysis buffer with 0.1% Nonidet P-40 instead of 1%). Then elution was done with the washing buffer supplemented with 40 mM phenyl phosphate. Fractions were collected and analyzed for protein content by silver staining and for Tyr(P) content by immunoblotting. The peak of tyrosine phosphorylated proteins, which coincided with the peak of eluted proteins, was pooled. Protein quantification was carried out with the micro BCA assay (Pierce).

Rabbit Immunization and Antisera Analysis-- Anti-Tyr(P) reactive proteins (1 × 1010 cell equivalents) in complete Freund's adjuvant were used to immunize two New Zealand White rabbits as follows. Two intradermic injections (50 µg) were followed by footpad injections with 25 µg of proteins. Bleeds were collected 15 days after each boost and screened for the production of antibodies. Because expression cloning relies on the detection of denatured antigens, immune antisera were tested by immunoblotting on UT7 cell lysates. The rabbit antiserum from the rabbit with the highest antibody titer and the lowest reactivity of the preimmune serum was selected for further screening of the cDNA library. This serum was also tested for its ability to precipitate proteins known to be tyrosine phosphorylated following Epo stimulation and was shown to contain anti-Shc antibodies (data not shown). IgG were purified and antibodies reacting with bacterial proteins were removed by absorption on column of bacterial proteins cross-linked to Sepharose beads (Hi TrapTM NHS-activated Sepharose from Amersham Pharmacia Biotech).

lambda EXlox Library Screening-- Absorbed IgG were used to screen a commercial (Novagen RD Systems Europe) 16-day-old murine embryo cDNA library in lambda EXlox vector, according to the manufacturer's instructions. Screening conditions were chosen to get an optimal signal-to-noise ratio and no reactivity with preimmune serum in immunoblot. This was obtained by initially testing the reactivity of the selected serum with a Shc clone previously isolated from the same library, a kind gift of J. Finidori (Paris, France). Briefly 2 × 106 recombinant plaques were initially screened with IgG (3 µg/ml) in 25 mM Tris-HCl, pH 7.5, 0.1% Tween, 140 mM NaCl, 3 mM KCl containing 5% (w/v) low fat powder milk. Colorimetric detection was carried out with anti-rabbit IgG conjugated to alkaline phosphatase and the bromochloroindolyl phosphate/nitro blue tetrazolium substrate (Promega). A second screen confirmed the reactivity of positive phages. Selected phages were plaque purified by conventional methods, and autosubcloning in plasmid vector was generated with the loxP-cre system. The insert cDNA sequence was determined using PerkinElmer Life Sciences automatic sequencing. Nucleotidic and protein data bases were screened with the BLAST program.

Immunoprecipitation, MalE Precipitations, and Immunoblotting-- Immunoprecipitations, MalE precipitations, and immunoblots were performed as described previously (4, 8). Proteins were immunoblotted with a mixture of 4G10 (0.3 µg/ml) and PY72 (1 µg/ml) to detect tyrosine phosphorylated proteins, with anti-Gbeta antibodies (1 µg/ml), anti-EpoR antibodies (1 µg/ml), or anti-JAK2 antiserum (1:1000). Bound antibodies were detected by incubation with horseradish peroxidase-coupled secondary antibodies and the enhanced chemiluminescence system (Amersham Pharmacia Biotech).

Preparation of Cell Membranes-- After washing UT7 cells in phosphate-buffered saline, the cells were suspended in hypotonic buffer (10 mM Tris-HCl, pH 7.4, 10 mM KCl, 2 mM EDTA) in the presence of protease inhibitors and homogenized with a Dounce pestle. After addition of 0.25 M sucrose, nuclei and unbroken cells were removed by centrifugation at 375 × g, and a membrane enriched fraction was obtained by centrifuging the supernatant at 150,000 × g for 45 min. The resulting membrane pellet was stored at -80 °C in 25 mM Hepes, pH 7.5, 150 mM NaCl, 5 mM EGTA, 10% glycerol or resuspended in appropriate buffer and used immediately for [35S]GTPgamma S binding. CHO-ER membranes were prepared as described previously (50).

ADP-ribosylation Assay-- ADP-ribosyltransferase activity was measured by following the incorporation of [32P]ADP-ribose (51). To assess the activity present in immunoprecipitates, immune complexes bound to protein G-Sepharose were washed in 50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1 mM ATP, and 0.1 mM GTP. Immunoprecipitated proteins were suspended in 50 µl of the same buffer containing 2 µCi of adenylate [32P]NAD (PerkinElmer Life Sciences; 800 Ci/mmol) and 7 µg/ml activated pertussis toxin. The toxin (17 µg/ml) was preactivated immediately before use for 1 h at room temperature in 50 mM Tris-HCl, pH 7.5, containing 62.5 mM dithiothreitol. ADP-ribosylation was carried out at 37 °C for 1 h, and the reaction was stopped by adding SDS sample buffer. Samples were boiled for 5 min, and the proteins were separated on a 10% SDS-polyacrylamide gel followed by transfer to nitrocellulose and autoradiography.

To assess the effect of Epo on pertussis toxin-induced ADP-ribosylation in cell membranes, membranes (50 µg) were initially incubated in 35 µl of buffer A (25 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA, 100 µM GTP, 10% glycerol) with or without Epo for 10 min at 37 °C. Other additions or deletions are as noted under "Results" and in the figure legends. Then membranes were combined with 35 µl of 2× buffer B (100 mM Tris-HCl, pH 7.5, 2 mM EDTA, 2 mM ATP, 0.2 mM GTP). After addition of adenylate [32P]NAD and activated pertussis toxin in 1× buffer B, ADP-ribosylation was performed as described above.

GTPgamma S Binding Assay-- The [35S]GTPgamma S binding was measured as described (52) with slight modifications. Membranes (~30 µg) were suspended in an assay volume of 50 µl of buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 100 mM NaCl, 10 µM GDP. Following a preincubation of membranes in the presence or absence of Epo for 15 min at 30 °C, the assay was initiated by adding [35S]GTPgamma S (New England Nuclear, 1250 Ci/mmol) to yield a final concentration of 0.3 nM. Nonspecific binding was measured in the presence of 100 µM unlabeled GTP. After 60 min at 30 °C, 0.5 ml of ice-cold buffer containing 20 mM Hepes, pH 7.4, 20 mM MgCl2, 100 mM NaCl, 100 µM GTP was added. Bound and free [35S]GTPgamma S were separated by filtration over glass fiber filters and three washings in the same buffer without GTP.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Screening of a Bacterial Expression Library with Antibodies Specific for Anti-Tyr(P) Reactive Fractions of Epo-stimulated Cells-- To purify proteins that become tyrosine phosphorylated upon Epo stimulation and their associated proteins, our initial concern was to get a high level of tyrosine phosphorylation. UT7 cells were selected for their high surface EpoR expression (~7000 receptors/cell) and their ability to proliferate in response to Epo. An optimal system was obtained by stimulating the cells with 10 units/ml Epo for 10 min at 37 °C and adding pervanadate (100 µM vanadate and 50 µM H2O2) for the last 2 min of stimulation. The low pervanadate concentration used did not modify the basal level of tyrosine phosphorylated proteins in the absence of Epo but allowed a significant increase of Epo-induced tyrosine phosphorylation (data not shown). Epo-stimulated cells were solubilized, the soluble fraction was loaded on anti-Tyr(P) column, and anti-Tyr(P)-reactive fractions were eluted with phenyl phosphate. As shown in Fig. 1A, most of tyrosine phosphorylated proteins present in Epo stimulated cells (lane 1) were purified on the anti-Tyr(P) column (lane 4). Comparison of the silver-stained protein profiles of the anti-Tyr(P) reactive fractions with the anti-Tyr(P) Western blotting profiles of the same fractions revealed that the purified proteins contained several proteins that were not tyrosine phosphorylated (data not shown). Proteins recovered from the column represented about 0.06% of solubilized proteins, a value in good agreement with EGF receptor substrates previously isolated with a similar procedure (20). Polyclonal antisera were generated using the entire pool of anti-Tyr(P) reactive proteins as immunogen (see "Experimental Procedures"). We next used these antibodies for immunological screening of a murine embryo cDNA library in lambda EXlox vector and identified several positive plaques. One of the cDNA encoded the Gbeta 2 subunit of heterotrimeric G proteins and is the subject of the present study. It contained the entire coding sequence of the Gbeta 2 subunit of heterotrimeric G proteins and the 5' noncoding sequence (53). We first wanted to exclude the possibility that the Gbeta 2 clone was isolated because of the cross-reactivity of the antibodies used for expression cloning with a protein present in the immunogen but different from Gbeta 2. As shown in Fig. 1B the Gbeta protein was detected by immunoblotting with anti-Gbeta antibodies in UT7 cell lysates as well as in anti-Tyr(P) reactive proteins purified from the soluble fraction of Epo-stimulated cells. As expected Gbeta was not present in a preparation of purified proteins isolated from nonstimulated cells. Thus, the isolation of the Gbeta cDNA with the expression cloning strategy suggests that an heterotrimeric G protein could potentially be tyrosine phosphorylated or associated with a tyrosine-phosphorylated protein upon Epo activation.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Gbeta detection in anti-Tyr(P) affinity purified proteins from Epo-stimulated cells. A, immunoaffinity chromatography. Epo- and serum-starved UT7 cells were stimulated with 10 units/ml Epo for 10 min at 37 °C. Cell lysates were loaded on anti-phosphotyrosine (pTyr) column as described under "Experimental Procedures." Proteins bound to the column were eluted with 40 mM phenyl phosphate. Proteins before purification (lane 1) in the column flow-through (lane 2) and in phenyl phosphate eluted proteins (lanes 3-5) were separated by SDS-PAGE and transferred to nitrocellulose membrane. Tyrosine phosphorylated proteins extracted from 2 × 105 cells were detected by immunoblotting with anti-Tyr(P) antibodies. B, Gbeta detection in anti-Tyr(P) reactive fractions. Starved UT7 cells were stimulated (+) or not (-) with 10 units/ml Epo for 10 min at 37 °C. Cell lysates were loaded on anti-phosphotyrosine column and anti-Tyr(P) reactive fractions were pooled. Purified proteins (PP, 5 × 106 cell equivalents), or total cell lysates (Lysate, 2 × 105 cell equivalents) were analyzed by SDS-PAGE and immunoblotting with anti-Gbeta antibodies.

Gbeta Subunit Associates with EpoR-- When Gbeta was immunoprecipitated from Epo-stimulated UT7 cells, we never detected a tyrosine phosphorylated form of the protein by immunoblotting with anti-Tyr(P) antibodies. This suggests that Gbeta is not phosphorylated upon Epo activation. Because Gbeta was present in anti-Tyr(P) reactive fractions (Fig. 1B), we hypothesized that Gbeta may have been copurified because of its association with another tyrosine-phosphorylated protein upon Epo stimulation. We then wanted to determine whether Gbeta was associated with the EpoR, one of the highly phosphorylated proteins upon Epo activation (4). UT7 cells were incubated or not with Epo at 37 °C for various times, and after cell solubilization, the EpoR was precipitated. As shown in Fig. 2A, immunoblotting with anti-Gbeta antibodies revealed the presence of Gbeta when cell lysates were precipitated with anti-EpoR antiserum but not with preimmune serum. The amount of Gbeta coprecipitated with EpoR decreased following Epo activation, suggesting that Gbeta is constitutively associated with EpoR and dissociates from the activated receptor. We extended our analysis to determine whether the interaction between Gbeta and EpoR could also be evidenced in vitro. Proteins binding to the cytoplasmic region of the EpoR were isolated from UT7 cell lysates, using a recombinant fusion protein between MalE and the cytoplasmic region of EpoR or a control MalE protein bound to amylose resin (Fig. 2B). When bound proteins were analyzed by immunoblotting with anti-Gbeta antibodies, Gbeta was detected only when MalE-EpoR fusion protein was used. We conclude that Gbeta binds to EpoR both in vivo and in vitro and that the interaction between Gbeta and EpoR occurs through the intracellular region of EpoR.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Gbeta association with erythropoietin receptor in UT7 cells. A, immunoprecipitation of Gbeta with anti-EpoR antibodies. Epo-starved UT7 cells were incubated with 10 units/ml Epo for the indicated time at 37 °C and then lysed. Cell lysates were immunoprecipitated with anti-EpoR antiserum (EpoR) or preimmune serum (C). Precipitated proteins (2 × 107 cell equivalents), and whole lysates (5 × 105 cell equivalents) were analyzed by SDS-PAGE and anti-Gbeta immunoblotting. B, in vitro association of EpoR intracellular domain with Gbeta . Lysates from UT7 cells (1.5 × 107) were incubated with immobilized MalE or MalE-EpoR fusion proteins. Bound proteins were resolved by SDS-PAGE and analyzed by anti-Gbeta immunoblotting.

Galpha i Subunit Associates with EpoR-- G proteins are associated to seven transmembrane receptors in an heterotrimeric form where the alpha  subunit is associated to beta /gamma . Because EpoR is not a "classical" G protein-coupled receptor, we investigated whether only Gbeta binds to the EpoR or whether the alpha  chain of G proteins was also associated to the EpoR. Several forms of Galpha were identified in UT7 cells by immunoblotting including Gi, Gs, and Gq. Our initial attempt to detect Galpha coprecipitated with the EpoR by immmunoblotting was unsuccessful because of the high nonspecific background in the region of Galpha migration. We used another method to investigate whether Galpha was bound to the EpoR, assuming that Gi/o would be a good candidate because a pertussis toxin-sensitive G protein has been shown to be required for Epo-dependent calcium activation in erythroid precursors (40). The alpha  subunit was detected by following the in vitro incorporation of [32P]ADP-ribose in the presence of preactivated pertussis toxin. This toxin catalyzes the ADP-ribosylation of alpha i/o/t subunits of G proteins. alpha t expression is restricted to the nervous system, and alpha o is not expressed in erythroid precursors or erythroleukemia cells (40, 54). This was confirmed in UT7 cells. Indeed we did not detect alpha o protein by immunoblotting with anti-Galpha o antibodies. In initial experiments we observed that a 41-kDa band was ADP-ribosylated in vitro in UT7 membranes. Labeling was linear for up to 1 h and pertussis toxin-dependent (data not shown). Therefore, this band is presumptively referred to as Galpha i, the alpha  subunit of the inhibitory guanine nucleotide regulatory protein.

The EpoR was immunoprecipitated from the soluble fraction of UT7 cells, and the ADP-ribosyltransferase activity present in the precipitates was measured. Fig. 3 illustrates that Galpha i coprecipitated with the EpoR in resting UT7 cells, and cell stimulation with Epo decreased the amount of ADP-ribosylated alpha i associated with the EpoR. On the contrary, the amount of EpoR remained constant. The G protein-EpoR complex was recovered in the 150,000 × g supernatant of solubilized cells and thus corresponded to solubilized complexes and not to membrane fragments (data not shown). These data show that Galpha i is constitutively bound to the EpoR, more likely as an alpha /beta /gamma heterotrimer because Galpha i is a better substrate for PT in its heterotrimeric form (51, 55). They also suggest that the G protein dissociates from the EpoR upon activation. To exclude the possibility that the G protein was precipitated by anti-EpoR antiserum because the EpoR and the G protein share a common epitope, the association was also studied both in cells that express an exogeneous EpoR and in cells that do not express EpoR. In MO7E cells expressing a murine EpoR, ADP-ribosylated alpha i was coprecipitated with EpoR but no 41-kDa band was detected in cells that do not express EpoR (Fig. 4A).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Coprecipitation of Galpha i with EpoR in UT7 cells. Lysates from Epo-starved UT7 cells (1 × 107 cell equivalents), stimulated (+) or not (-) for 10 min with 10 units/ml Epo, were immunoprecipitated (IP) with anti-EpoR antiserum (EpoR) or preimmune serum (C). Immunoprecipitates were subjected to in vitro ADP-ribosylation as described under "Experimental Procedures." The proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane, and Galpha i was visualized by autoradiography. EpoR protein was detected by immunoblotting.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Galpha i association with EpoR in EpoR transfected cells and in erythroid progenitors. A, MO7E cells expressing murine EpoR (MO7E-ER) or not (MO7E) were stimulated with 10 units/ml Epo for 30 min. Cell lysates (1 × 107 cell equivalents) were immunoprecipitated with anti-EpoR antiserum. B, erythroid progenitors were deprived of growth factor and stimulated (+) or not (-) with Epo for the indicated time. After cell solubilization the EpoR was precipitated, and Galpha i was detected in the precipitates by in vitro ADP-ribosylation followed by autoradiography.

Having established an association between G protein and EpoR in cell lines that express endogenous or exogenous receptor, we wanted to determine whether G protein binding to EpoR holds true in normal human erythroid progenitors. CD36+ red cell progenitors were isolated after culture of CD34+ cells from umbilical cord blood (49) and then deprived of growth factors and stimulated or not with Epo. The data shown in Fig. 4B demonstrate that an association between alpha i and EpoR also exists in normal erythroid progenitors and that Epo significantly reduces the amount of Gi associated with the EpoR.

Gi Binds to the C-terminal End of EpoR Cytoplasmic Region-- To identify the region of the EpoR involved in G protein binding, we first examined Gi association to EpoR in TF-1 cells (Fig. 5). This human erythroleukemia cell line was previously shown to overexpress an abnormal EpoR caused by a deletion of the 96 C-terminal amino acids, together with a minor expression of full-length EpoR (47, 56). TF-1 cells were solubilized, and the Galpha i protein coprecipitated with EpoR was detected by in vitro ADP-ribosylation in the presence of pertussis toxin. Very little Galpha i was detected in anti-EpoR immunoprecipitates either before or after Epo stimulation, suggesting that these cells have a defect in Galpha i binding to EpoR. When the cells were infected with a virus encoding a normal murine EpoR (TF-1-ER), Galpha i binding to the EpoR was restored. This suggests that the C-terminal end of EpoR is necessary for Galpha i binding to EpoR.



View larger version (44K):
[in this window]
[in a new window]
 
Fig. 5.   Defect in Gi association to EpoR in TF-1 cells. TF-1 cells or TF-1 expressing murine EpoR (1 × 107 cell equivalents) were deprived of growth factor and stimulated (+) or not (-) with Epo for 15 min. Cell lysates were immunoprecipitated (IP) with anti-EpoR antiserum (EpoR) or preimmune serum (C) and Galpha i coprecipitated with EpoR was detected by in vitro ADP-ribosylation.

To examine this possibility in greater detail we next studied the association of Galpha i with wild-type murine EpoR or C-terminal deletion mutants (Fig. 6A) expressed in FDCP-1 cells. In FDCP-1 cells transfected with the murine EpoR deletion mutants -41 and -24, no Galpha i was found associated with EpoR, and a weak binding was detected in mutant -20 (Fig. 6B). The absence of binding was not due to a decrease in EpoR surface expression because FDCP-1 cells transfected with wild-type EpoR, -41, -24, and -20 EpoR C-terminal deletion mutants expressed, respectively, 695, 580, 685, and 1820 125I-Epo binding sites on the cell surface. Galpha i binding to the -5 EpoR deletion mutant and to EpoR mutant F1-Y58 deleted between amino acids 377 and 431 was similar to the binding to the wild-type receptor. We controlled that a similar fraction of EpoR bound 125I-Epo was precipitated with anti-EpoR antibodies for the different EpoR mutants. In addition G protein expression, as detected by anti-Gbeta immunoblotting was similar in FDCP-1 cells transfected with either wild-type EpoR or EpoR deletion mutants (data not shown). These results show that the region between amino acids 459 and 479 in the C-terminal end of EpoR is necessary for heterotrimeric G protein binding to the EpoR. It cannot be excluded that amino acids 432-458, also present in F1-Y58 mutant, contribute to the binding.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Gi protein binding to the C-terminal end of EpoR intracytoplasmic region. FDCP-1 cells or FDCP-1 cells expressing murine EpoR or deletion mutants of EpoR (1 × 107 cell equivalents) were starved of Epo and stimulated for 30 min with Epo. A, schematic representation of the different EpoR mutants. B, Galpha i coprecipitated with EpoR as performed in Fig. 3. WT, wild type.

Epo Induces the Release of G Protein from the EpoR-- A decrease in G protein association with EpoR following Epo addition was constantly observed in the different hematopoietic cells studied. The kinetic of G protein binding to EpoR was analyzed in UT7 cells stimulated or not with Epo for various times at 37 °C. The amount of Gi coprecipitated with the EpoR in the soluble fraction was determined by measuring the 32P incorporated in the 41-kDa protein following in vitro ADP-ribosylation (Fig. 7). Epo induced a rapid decrease in the amount of Galpha i bound to the EpoR. About 50% of the binding was lost after 10 min of incubation, and then the amount of binding decreased more slowly. We conclude that heterotrimeric Gi is constitutively associated with EpoR and Epo induces the dissociation of EpoR-bound Gi. To determine whether Epo-induced JAK2 tyrosine kinase activation is required for Gi release from the EpoR, we investigated whether the decrease in EpoR-bound Gi was observed in 32D cells expressing EpoR W282R mutant. This mutant has lost the ability to bind JAK2 and activate the kinase in response to Epo (Refs. 5 and 48 and data not shown). As shown in Fig. 8 Epo activation induced Gi release in cells expressing the normal as well as the mutant receptor. Thus JAK2 activation is not required for the release of EpoR-bound Gi.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 7.   Decrease of Gi coprecipitated with EpoR after Epo stimulation. UT7 cells were deprived of growth factor and stimulated with 10 units/ml Epo for the indicated time. Cell lysates were immunoprecipitated with anti-EpoR antibodies. The immunoprecipitates were subjected to in vitro ADP-ribosylation. The proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane. Galpha i was visualized by autoradiography and the amount of 32P present in the bands was quantified with a PhosphorImager. Data are the means ± S.E. of three individual experiments.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Decrease of Gi coprecipitated with EpoR in 32D cells expressing EpoR mutant defective in Jak2 activation. 32D cells expressing murine EpoR or EpoR mutant W282R (1 × 107 cell equivalents) were starved of Epo and stimulated for 30 min with 10 units/ml Epo. Analysis of Galpha i coprecipitated with EpoR was followed by in vitro ADP-ribosylation. WT, wild type.

G Protein Activation by Epo-- G protein-coupled receptors activate G proteins resulting in GDP exchange for GTP and heterotrimer dissociation in alpha  and beta gamma subunits. To investigate whether the G proteins associated with EpoR are activated upon receptor stimulation with Epo, we first monitored alterations of pertussis toxin-catalyzed ADP-ribosylation in isolated cell membranes. This assay was used to assess Galpha i protein subunit conformational changes, because the alpha  subunit serves as a good substrate for the toxin only when G proteins are in the trimeric form (51, 55). Results showed that preincubation of UT7 cell membranes with Epo inhibited subsequent ADP-ribosylation of the 40-kDa substrate (Fig. 9A, lanes 4 and 5). The action of Epo is dependant on the Mg2+ concentration (Fig. 9A, lanes 1-4), which is also essential for Gi protein trimer dissociation (57). GTPgamma S, the nonhydrolyzable GTP analog that causes alpha beta gamma subunit dissociation and irreversibly activates Gi, inhibited pertussis toxin-catalyzed ADP-ribosylation independently of Epo. These data show that Epo induces an alteration in Galpha i and suggest that Epo activation leads to the heterotrimer dissociation.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of Epo on pertussis toxin-induced ADP-ribosylation and on [35S]GTPgamma S binding to membranes. A, inhibition of pertussis toxin-induced ADP-ribosylation by Epo. UT7 cell membranes were preincubated with 10 units/ml Epo or 100 µM GTPgamma S for 10 min in the presence of increasing concentrations of Mg2+ using Mg2+-EDTA buffer before ADP-ribosylation by pertussis toxin. The proteins were separated by SDS-PAGE, and Galpha i was visualized by autoradiography. B, increase in [35S]GTPgamma S binding by Epo. UT7 or CHO-ER membranes were pretreated or not with Epo for 15 min, and [35S]GTPgamma S binding was determined as described under "Experimental Procedures." Data are the means ± S.E. of duplicate samples and are expressed as percentages of values from untreated cell membranes.

GPCR-catalyzed activation of G proteins is associated with an enhancement of their GTP binding. We have therefore examined the effect of Epo on the nonhydrolyzable GTP analog GTPgamma S binding to cell membranes. In the presence of Epo, the amount of nucleotide that specifically bound was increased by 18% in UT7 cell membranes and by 56% in CHO-ER cell membranes (Fig. 9B). The increase in [35S]GTPgamma S binding observed in Epo-activated CHO-ER cells is similar to the increase detected in HEK293 cells expressing a GPCR, the Mel1a melatonin receptor, following activation with melatonin (Ref. 52 and data not shown).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present investigation, we provide the first demonstration of the physical association between the heterotrimeric G protein of the Gi family and the erythropoietin receptor, both in hematopoietic cell lines and in human normal erythroid progenitor cells. The Gi protein associated with the EpoR is more likely in an heterotrimeric conformation. Indeed both Gbeta and Galpha i, identified as a 41-kDa ADP-ribosylated band, coprecipitated with the EpoR. By utilizing natural and engineered truncated EpoR mutants, we showed that the intracellular C-terminal end of the EpoR is required for G protein association. The association between the G protein and EpoR is constitutive. Classical G protein-coupled receptors are believed to associate with G proteins following ligand activation (58), although they may in some cases be preassociated. Actually, the association between a Gi protein and a single-spanning transmembrane receptor has previously been reported. A peptide corresponding to the intracytoplasmic sequence of beta -1,4-galactosyltransferase, the sperm receptor for the mouse egg, bound a heterotrimeric G protein that contained the Galpha i subunit (30). Galpha i was found to copurify with the beta  chain of insulin receptor isolated from adipocyte plasma membranes (31). A transient association between Galpha i and the EGF receptor also occurred in rat hepatocytes after ligand activation (29, 59), and Galpha i and Gbeta were recently shown to constitutively bind the IGF-I receptor (60). A region of 18 amino acids in the C terminus of EpoR is necessary for Gi binding to EpoR. A 14-residue sequence in the IGF-II receptor, with several basic residues, presents structural similarity with the terminal portion of the third cytoplasmic loops of most G-coupled receptors. This sequence activates and directly interacts with Gi proteins (61, 62), but the EpoR cytoplasmic domain does not contain such a G protein-binding motif. Another possibility is that the interaction between Gi and EpoR occurs through an adaptor protein bound to the EpoR. The tyrosine kinase Jak2 and the docking protein IRS2 constitutively bind to the EpoR membrane proximal region (5, 15). Because G protein binding to EpoR involves the C-terminal end of the receptor, these proteins are unlikely to play a role of adaptor between G protein and EpoR, and another component whose nature is unknown could be required. The ability of the EpoR mutant W282R to bind Gi in the absence of Jak2 binding also excludes Jak2 as a potential adaptor.

Epo induces the release of Gi from the EpoR. Hallak and co-workers (60) have recently reported that heterotrimeric Gi is constitutively associated with IGF-I receptor and that IGF-I also induces the release of the Gbeta gamma subunit from the IGF-I receptor. Jak2 tyrosine kinase is probably not required for Gi protein release from the EpoR because this process still occurs in 32D cells that express the EpoR mutant W282R defective in Jak2 activation. It cannot be excluded that other tyrosine kinases involved in Epo activation such as Lyn, Syk, or c-Fes (6-8) may be required for Gi release. Although Jak2 plays a pivotal role in EpoR signaling (63, 64), Gi protein release from EpoR could participate in a new Jak2-independent pathway.

Following activation of heterotrimeric G proteins by classical GPCR, both the alpha  and the beta gamma subunits dissociate from the receptor and activate target effectors (58, 65). Epo inhibited PT-catalyzed ADP-ribosylation of Galpha i in UT7 cell membranes in a Mg2+-dependant manner, suggesting that the alpha  subunit also dissociates from the beta gamma subunit complex of the heterotrimeric G protein after Epo activation. Similar data were obtained in membranes activated with other single-spanning transmembrane receptors, such as insulin and IL-1 (66, 67), suggesting that other receptors that GPCR can modify G protein conformation and potentially induce trimer dissociation.

In addition to demonstrating the physical association of Gi with the EpoR, our data show that Epo increases GTPgamma S binding in cell membranes, providing evidence that EpoR can activate G proteins. Some studies have suggested that Epo may increase adenylate cyclase activity and cAMP levels (40, 68), whereas others did not report any modification of cAMP (69). However, to our knowledge, no studies have reported a decrease in cAMP levels in response to Epo stimulation. In erythroid precursors a PT-sensitive Galpha i2 has been demonstrated to regulate an Epo-modulated Ca2+ channel (40, 41), and G protein activation by GTPgamma S mimics the rise in [Ca2+]i (41). These data support an important role for heterotrimeric G proteins in the signaling pathways of Epo. Epo-stimulated changes in [Ca2+]i were not detected in nonhemoglobinized or poorly hemoglobinized early erythroblasts with a large proliferative capacity. In contrast, in hemoglobinized late erythroblasts with a reduced proliferative capacity, Epo increased [Ca2+]i (42), suggesting that regulation of [Ca2+]i may be restricted to rather mature precursors. Recently, tyrosine 460 in the intracytoplasmic domain of EpoR was shown to be critical for Epo-stimulated Ca2+ influx, in CHO cells as well as in Ba/F3 hematopoietic cells transfected with EpoR mutants (70). Interestingly the C-terminal end of EpoR required for Gi binding to EpoR includes the tyrosine 460 (Fig. 6). Although in erythroid precursors the role of Gi protein in Epo-induced Ca2+ activation has been clearly established, transducers that bind to Tyr460 have not yet been identified (70). Future investigations should allow the identification of the components that participate in G protein and calcium activation by Epo.

Heterotrimeric Gi proteins could be important intermediates in cell proliferation mediated by hematopoietic growth factors. Indeed PT inhibits cell growth induced by IL-1 (38), IL-3 (35), CSF-1 (35), and GM-CSF (36). Expression of a dominant negative Galpha i2 inhibits cell proliferation mediated by CSF-1 receptor in macrophages (39) and cell proliferation and transformation in NIH3T3 cells transfected with the oncogenic form of the CSF-1 receptor v-fms (71). PT inhibits Epo-stimulated erythroid colonies formation in rat erythroid progenitor cells from fetal liver (72). This suggests that Gi proteins could be involved in Epo-dependent cell growth. Further studies will be required to elucidate the functional significance of G protein coupling to EpoR.

In conclusion, the results presented here show that Gi protein is physically associated with EpoR. Epo activates G protein in cell membranes and induces the release of Gi bound to the receptor in hematopoietic cells. Our data strongly suggest that Gi proteins are important components in Epo signaling.


    ACKNOWLEDGEMENTS

We thank Dr. Sylvie Hermouet for very helpful discussions and for kindly providing anti-G antibodies, Dr. Sigmund Fischer for fruitful discussions, Dr. G. D. Longmore for providing us 32D cells expressing wild-type and mutant EpoR, Dr. E. Goldwasseur for CHO-ER cell line, and Dr. Catherine Lacombe for MO7E-ER and TF-1-ER cell lines. We are indebted to Dr. Sylvie Gisselbrecht for continuous support and for critically reviewing the manuscript. We gratefully acknowledge the expert technical assistance of Christelle Chardes, Jean-Marc Freyssinier, and Odile Muller.


    FOOTNOTES

* This work was supported by grants from the "Comité de Paris de la Ligue Nationale contre le Cancer" (Associate Laboratory 8).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: INSERM U363, ICGM, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.Fax: 331-40-51-65-10; E-mail: duprez@cochin.inserm.fr.

Published, JBC Papers in Press, October 25, 2000, DOI 10.1074/jbc.M003527200


    ABBREVIATIONS

The abbreviations used are: Epo, erythropoietin; EpoR, erythropoietin receptor; EGF, epidermal growth factor; IGF, insulin-like growth factor; G protein, heterotrimeric GTP-binding protein; GPCR, G protein-coupled receptor; PT, pertussis toxin; PAGE, polyacrylamide gel electrophoresis; IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; CSF-1, colony-stimulating factor-1; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate; CHO, Chinese hamster ovary.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Damen, J., and Krystal, G. (1996) Exp. Hematol. 24, 1455-1459[Medline] [Order article via Infotrieve]
2. Klingmuller, U. (1997) Eur. J. Biochem. 249, 637-647[Abstract]
3. Miura, O., D'Andrea, A., Kabat, D., and Ihle, J. N. (1991) Mol. Cell. Biol. 11, 4895-4902
4. Dusanter-Fourt, I., Casadevall, N., Lacombe, C., Muller, O., Billat, C., Fischer, S., and Mayeux, P. (1992) J. Biol. Chem. 267, 10670-10675[Abstract/Free Full Text]
5. Witthuhn, B., Quelle, F., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. (1993) Cell 74, 227-236[Medline] [Order article via Infotrieve]
6. Hanazono, Y., Chiba, S., Sasaki, K., Mano, H., Yazaki, Y., and Hirai, H. (1993) Blood 81, 3193-3196[Abstract]
7. Tilbroook, P. A., Ingley, E., Williams, J. H., Hibbs, M. L., and Klinken, S. P. (1997) EMBO J. 16, 1610-1619[Abstract/Free Full Text]
8. Duprez, V., Blank, U., Chretien, S., Gisselbrecht, S., and Mayeux, P. (1998) J. Biol. Chem. 273, 33985-33990[Abstract/Free Full Text]
9. Gobert, S., Chrétien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt, I., Groner, B., Lacombe, C., Gisselbrecht, S., and Mayeux, P. (1996) EMBO J. 15, 2434-2441[Abstract]
10. Tauchi, T., Feng, G., Shen, R., Hoatlin, M., Bagby, G. J., Kabat, D., Lu, L., and Broxmeyer, H. (1995) J. Biol. Chem. 270, 5631-5635[Abstract/Free Full Text]
11. Damen, J., Liu, L., Cutler, R., and Krystal, G. (1993) Blood 82, 2296-2303[Abstract]
12. Ren, H., Komatsu, N., Shimizu, R., Okada, K., and Miura, Y. (1994) J. Biol. Chem. 269, 19633-19638[Abstract/Free Full Text]
13. Miura, O., Miura, Y., Nakamura, N., Quelle, F., Witthuhn, B., Ihle, J., and Aoki, N. (1994) Blood 84, 4135-4141[Abstract/Free Full Text]
14. Odai, H., Sasaki, K., Iwamatsu, A., Hanazono, Y., Tanaka, T., Mitani, K., Yazaki, Y., and Hirai, H. (1995) J. Biol. Chem. 270, 10800-10805[Abstract/Free Full Text]
15. Verdier, F., Chretien, S., Billat, C., Gisselbrecht, S., Lacombe, C., and Mayeux, P. (1997) J. Biol. Chem. 272, 26173-26178[Abstract/Free Full Text]
16. Lecoq-Lafon, C., Verdier, F., Fichelson, S., Chretien, S., Gisselbrecht, S., Lacombe, C., and Mayeux, P. (1999) Blood 93, 2578-2585[Abstract/Free Full Text]
17. Chin, H., Saito, T., Arai, A., Yamamoto, K., Kamiyama, R., Miyasaka, N., and Miura, O. (1997) Biochem. Biophys. Res. Commun. 239, 412-417[CrossRef][Medline] [Order article via Infotrieve]
18. Fazioli, F., Minichiello, L., Matoskova, B., Wong, W., and Di, F. P. (1993) Mol. Cell. Biol. 13, 5814-5828[Abstract]
19. Glenney, J. J., and Zokas, L. (1989) J. Cell Biol. 108, 2401-2408[Abstract]
20. Fazioli, F., Bottaro, D., Minichiello, L., Auricchio, A., Wong, W., Segatto, O., and Di, F. P. (1992) J. Biol. Chem. 267, 5155-5161[Abstract/Free Full Text]
21. Liang, M., and Garrison, J. (1991) J. Biol. Chem. 266, 13342-13349[Abstract/Free Full Text]
22. Luttrell, L., Hewlett, E., Romero, G., and Rogol, A. (1988) J. Biol. Chem. 263, 6134-6141
23. Nishimoto, I., Murayama, Y., Katada, T., Ui, M., and Ogata, E. (1989) J. Biol. Chem. 264, 14029-14038[Abstract/Free Full Text]
24. Luttrell, L., van, B. T., Hawes, B., Koch, W., Touhara, K., and Lefkowitz, R. (1995) J. Biol. Chem. 270, 16495-16498[Abstract/Free Full Text]
25. Moxham, C., and Malbon, C. (1996) Nature 379, 840-844[CrossRef][Medline] [Order article via Infotrieve]
26. Fedorov, Y., Jones, N., and Olwin, B. (1998) Mol. Cell. Biol. 18, 5780-5787[Abstract/Free Full Text]
27. Imboden, J., Shoback, D., Pattison, G., and Stobo, J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 5673-5677
28. Cenciarelli, C., Hohman, R., Atkinson, T., Gusovsky, F., and Weissman, A. (1992) J. Biol. Chem. 267, 14527-14530[Abstract/Free Full Text]
29. Yang, L., Baffy, G., Rhee, S., Manning, D., Hansen, C., and Williamson, J. (1991) J. Biol. Chem. 266, 22451-22458[Abstract/Free Full Text]
30. Gong, X., Dubois, D., Miller, D., and Shur, B. (1995) Science 269, 1718-1721
31. Krieger-Brauer, H., Medda, P., and Kather, H. (1997) J. Biol. Chem. 272, 10135-10143[Abstract/Free Full Text]
32. Frazier, W., Gao, A., Dimitry, J., Chung, J., Brown, E., Lindberg, F., and Linder, M. (1999) J. Biol. Chem. 274, 8554-8560[Abstract/Free Full Text]
33. Lippert, E., Baltensperger, K., Jacques, Y., and Hermouet, S. (1997) FEBS Lett. 417, 292-296[CrossRef][Medline] [Order article via Infotrieve]
34. Ghose, S., Porzig, H., and Baltensperger, K. (1999) J. Biol. Chem. 274, 12848-12854[Abstract/Free Full Text]
35. He, Y., Hewlett, E., Temeles, D., and Quesenberry, P. (1988) Blood 71, 1187-1195[Abstract]
36. McColl, S., Kreis, C., Di, P. J., Borgeat, P., and Naccache, P. (1989) Blood 73, 588-591[Abstract]
37. Imamura, K., Dianoux, A., Nakamura, T., and Kufe, D. (1990) EMBO J. 9, 2423-2428[Abstract]
38. Zumbihl, R., Dornand, J., Fischer, T., Cabane, S., Rappuoli, R., Bouaboula, M., Casellas, P., and Rouot, B. (1995) J. Immunol. 155, 181-189[Abstract]
39. Corre, I., and Hermouet, S. (1995) Blood 86, 1776-1783[Abstract/Free Full Text]
40. Miller, B., Foster, K., Robishaw, J., Whitfield, C., Bell, L., and Cheung, J. (1991) Blood 77, 486-492[Abstract]
41. Miller, B., Bell, L., Hansen, C., Robishaw, J., Linder, M., and Cheung, J. (1996) J. Clin. Invest. 98, 1728-1736[Abstract/Free Full Text]
42. Miller, B., Cheung, J., Tillotson, D., Hope, S., and Scaduto, R. J. (1989) Blood 73, 1188-1194[Abstract]
43. Mayeux, P., Lacombe, C., Casadevall, N., Chretien, S., Dusanter, I., and Gisselbrecht, S. (1991) J. Biol. Chem. 266, 23380-23385[Abstract/Free Full Text]
44. Komatsu, N., Nakauchi, H., Miwa, A., Ishihara, T., Eguchi, M., Moroi, M., Okada, M., Sato, Y., Wada, H., Yawata, Y., Suda, T., and Miura, Y. (1991) Cancer Res. 51, 341-345[Abstract]
45. Kitamura, T., Tojo, A., Kuwaki, T., Chiba, S., Miyazono, K., Uraben, A., and Takaku, F. (1989) Blood 73, 375-380[Abstract]
46. Avanzi, G. C., Lista, P., Giovinazzo, B., Miniero, R., Saglio, G., Benetton, G., Coda, R., Cattoretti, G., and Pegoraro, L. (1988) Br. J. Haematol. 69, 359-366[Medline] [Order article via Infotrieve]
47. Chretien, S., Varlet, P., Verdier, F., Gobert, S., Cartron, J., Gisselbrecht, S., Mayeux, P., and Lacombe, C. (1996) EMBO J. 15, 4174-4181[Abstract]
48. Beckman, D. L., Lin, L. L., Quinones, M. E., and Longmore, G. D. (1999) Blood 94, 2667-2675[Abstract/Free Full Text]
49. Freyssinier, J., Lecoq-Lafon, C., Amsellem, S., Picard, F., Ducrocq, R., Mayeux, P., Lacombe, C., and Fichelson, S. (1999) Br. J. Haematol. 106, 912-922[CrossRef][Medline] [Order article via Infotrieve]
50. Jockers, R., Angers, S., DaSilva, A., Benaroch, P., Strosberg, A., Bouvier, M., and Marullo, S. (1999) J. Biol. Chem. 274, 28900-28908[Abstract/Free Full Text]
51. Tsai, S., Adamik, R., Kanaho, Y., Hewlett, E., and Moss, J. (1984) J. Biol. Chem. 259, 15320-15323[Abstract/Free Full Text]
52. Roka, F., Brydon, L., Waldhoer, M., Strosberg, A. D., Freissmuth, M., Jockers, R., and Nanoff, C. (1999) Mol. Pharmacol. 56, 1014-1024[Abstract/Free Full Text]
53. Chretien, S., Duprez, V., Maouche, L., Gisselbrecht, S., Mayeux, P., and Lacombe, C. (1997) Oncogene 15, 1995-1999[CrossRef][Medline] [Order article via Infotrieve]
54. Williams, A., Woolkalis, M., Poncz, M., Manning, D., Gewirtz, A., and Brass, L. (1990) Blood 76, 721-730[Abstract]
55. Neer, E., Lok, J., and Wolf, L. (1984) J. Biol. Chem. 259, 14222-14229[Abstract/Free Full Text]
56. Winkelmann, J. C., Ward, J., Mayeux, P., Lacombe, C., Schimmenti, L., and Jenkins, R. B. (1995) Blood 85, 179-185[Abstract/Free Full Text]
57. Bokoch, G. M., Katada, T., Northup, J. K., Ui, M., and Gilman, A. G. (1984) J. Biol. Chem. 259, 3560-3567[Abstract/Free Full Text]
58. Gilman, A. (1987) Annu. Rev. Biochem. 56, 615-649
59. Yang, L., Camoratto, A., Baffy, G., Raj, S., Manning, D., and Williamson, J. (1993) J. Biol. Chem. 268, 3739-3746[Abstract/Free Full Text]
60. Hallak, H., Seiler, A. E. M., Green, J. S., Ross, B. N., and Rubin, R. (2000) J. Biol. Chem. 275, 2255-2258[Abstract/Free Full Text]
61. Okamoto, T., Katada, T., Murayama, Y., Ui, M., Ogata, E., and Nishimoto, I. (1990) Cell 62, 709-717[Medline] [Order article via Infotrieve]
62. Okamoto, T., and Nishimoto, I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8020-8023[Abstract]
63. Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Cell 93, 397-409[Medline] [Order article via Infotrieve]
64. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., Van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 385-395[Medline] [Order article via Infotrieve]
65. Neer, E. (1995) Cell 80, 249-257[Medline] [Order article via Infotrieve]
66. Rothenberg, P. L., and Kahn, C. R. (1988) J. Biol. Chem. 263, 15546-15552[Abstract/Free Full Text]
67. O'Neill, L. A., Bird, T. A., Gearing, A. J., and Saklatvala, J. (1990) J. Biol. Chem. 265, 3146-3152[Abstract/Free Full Text]
68. Bonanou-Tzedaki, S., Setchenska, M., and Arnstein, H. (1986) Eur. J. Biochem. 155, 363-370[Abstract]
69. Tsuda, H., Sawada, T., Sakaguchi, M., Kawakita, M., and Takatsuki, K. (1989) Exp. Hematol. 17, 211-217[Medline] [Order article via Infotrieve]
70. Miller, B., Barber, D., Bell, L., Beattie, B., Zhang, M., Neel, B., Yoakim, M., Rothblum, L., and Cheung, J. (1999) J. Biol. Chem. 274, 20465-20472[Abstract/Free Full Text]
71. Corre, I., Baumann, H., and Hermouet, S. (1999) Oncogene 18, 6335-6342[CrossRef][Medline] [Order article via Infotrieve]
72. Billat, C., Delemer, B., Correze, C., and Haye, B. (1991) Biol. Neonate 60, 371-376[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.